DHT & 5-Alpha-Reductase in Development
Dihydrotestosterone, External-Genitalia Masculinization & 5-Alpha-Reductase-2 Deficiency (the Guevedoces)
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not applicable (developmental biology / inherited condition)
Reference only. Not medical advice.
What can go wrong
5-alpha-reductase-2 deficiency is an inherited cause of atypical genitalia at birth and carries the medical, psychological and decision-making burdens of any DSD, including historically irreversible early surgeries now subject to ethical reconsideration. Separately, the derived drug class (5-alpha-reductase inhibitors) used in adults for BPH and hair loss carries its own documented risks (sexual side effects, mood effects reported by some, and reports of persistent symptoms), and is contraindicated in pregnancy because blocking fetal DHT can feminize a male fetus, the same biology in reverse.
This is something to take to a clinician. The Atlas can tell you what is known about dht & 5-alpha-reductase in development in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Dihydrotestosterone (DHT) is the high-affinity androgen that masculinizes the external genitalia and prostate in the fetus. It is made from testosterone by 5-alpha-reductase, chiefly the type-2 isoenzyme (SRD5A2). Julianne Imperato-McGinley's studies of a cluster of 46,XY individuals in Salinas and other villages of the Dominican Republic, known locally as 'guevedoces' (roughly 'penis at twelve') and 'machihembra', showed that 5-alpha-reductase-2 deficiency yields ambiguous or apparently female external genitalia at birth despite normal testes, Wolffian structures and testosterone. At puberty the testosterone surge virilizes them, and many were raised female but adopted a male gender role. The work dissected testosterone-dependent from DHT-dependent events and directly inspired the development of finasteride for prostate enlargement and male-pattern hair loss.
The experiment of nature that separated testosterone from its more potent metabolite.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
In the fetus, testosterone diffuses into target tissue and is reduced to DHT by 5-alpha-reductase-2. DHT binds the androgen receptor with greater affinity and forms a more stable complex than testosterone, amplifying androgen signaling specifically where the enzyme is expressed, genital skin, urethra, prostate anlage. DHT drives fusion of the urethral folds, growth of the genital tubercle into a penis, scrotal formation and prostate development. Testosterone itself is sufficient for the internal Wolffian ducts. Thus in 5-ARD-2 deficiency the internal male tract is normal (testosterone-dependent) but the external genitalia are under-virilized (DHT-dependent).
Why puberty 'fixes' part of it
At puberty the large rise in circulating testosterone, plus residual activity of the type-1 isoenzyme (SRD5A2 deficiency spares SRD5A1), generates enough androgen signaling to drive phallic growth, muscle mass, voice change and libido, which is why affected individuals virilize markedly at adolescence. What does NOT fully recover are tissues that needed DHT during the fetal window: many have a small prostate, scant facial/body hair, and persistent hypospadias or a urogenital sinus. This dissociation is the crux of the science: it proved that some androgen targets are DHT-obligate while others run on testosterone.
What people get wrong
Often saidDHT deficiency means a man cannot virilize
ActuallyAt puberty most 5-ARD-2 individuals virilize substantially via testosterone and type-1 enzyme; the deficit is mainly in fetal/external and prostate/hair tissues.
Often saidFinasteride was discovered by chance
ActuallyFinasteride was rationally designed from the 5-ARD natural experiment, affected men had small prostates and no male-pattern baldness, suggesting blocking the enzyme could treat BPH and hair loss.
Who profits, and who pushes back
Critics of gender-identity over-reading
The Dominican cases are often cited as proof that hormones override rearing, but cultural recognition of a known local category ('guevedoces') and social factors complicate any simple biological-determinism reading.
What we do not know
- How much of the pubertal virilization is type-1 enzyme vs sheer testosterone mass?
- What explains the variable gender outcomes across and within 5-ARD cohorts?
At a glance
- Key enzyme
- 5-alpha-reductase type 2 (SRD5A2 gene)
- Defect
- Autosomal recessive 5-ARD-2 deficiency
- DHT vs T affinity
- DHT binds AR with higher affinity / slower dissociation
- Classic cohort
- Dominican Republic (Imperato-McGinley)
- Derived drug
- Finasteride (5-ARI), approved 1992/1997
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about DHT & 5-Alpha-Reductase in Development. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Imperato-McGinley et al., Science1974
Described 5-alpha-reductase deficiency in the Dominican kindred; separated DHT-dependent from T-dependent virilization
Imperato-McGinley et al., NEJM1979
Reported gender-role change from female to male at puberty in affected individuals, a landmark in psychosexual development
Andersson/Russell, two 5-alpha-reductase genes1990s
Cloned SRD5A1 and SRD5A2, explaining isoenzyme tissue distribution and the developmental phenotype